Bupa UK to cover EpiSwitch® CiRT for customers with cancer
-
Bupa
UK health insurance customers being considered for checkpoint inhibitor immunotherapy will now be offered the smart blood test, which accurately predicts a cancer patient's response to the treatment -
The OBD Bupa
UK partnership significantly enhances access to CiRT in theUK and reflects Bupa’s commitment to leveraging advanced precision medicine testing to transform cancer care
The EpiSwitch CiRT is a first-of-its-kind blood test that accurately predicts an individual cancer patient's therapeutic response to immune checkpoint inhibitors (ICIs), providing unique benefits for physicians in treatment planning and navigating complex decisions [1,2]. ICIs offer a real hope of durable disease control for some patients. Despite pre-screening with current standard tests such as tumor PD-L1 expression, these costly ICIs offer a long-term survival advantage to less than 1 in 4 patients [3], and many may become seriously ill and require hospital admission.
Under this new agreement between Bupa and OBD, Bupa health insurance customers
The CiRT test will also be available to doctors considering treating Bupa customers with an ICI, where decisions need to be made in the face of potential serious illness and lack of response to treatment.
“This agreement reflects our commitment to leverage advanced precision medicine testing to transform cancer care and provide doctors with the tools they need to make informed decisions. Together with Oxford BioDynamics, we aim to make a positive impact on the lives of all our customers living with cancer.”
Dr
“Current testing modalities lack the sensitivity, specificity and accuracy to identify those most likely to benefit from this class of therapy - the CiRT blood test is a first-of-its-kind test that addresses all of these shortcomings."
This news follows EpiSwitch CiRT’s sustained adoption in the US [4], where a unique CPT PLA reimbursement code for the test has been available for use by US payors since
-Ends-
References
[1]
[2] Hunter, E., et al. (2023). Development and validation of blood‐based predictive biomarkers for response to PD‐1/PD-L1 checkpoint inhibitors: evidence of a universal systemic core of 3D immunogenetic profiling across multiple oncological indications, Cancers 15(10), 2696. https://www.mdpi.com/2072-6694/15/10/2696
[3] Zhao, B.; Zhao, H.; Zhao, J. (2020). Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials, Therapeutic Advances in Medical Oncology, Vol. 12. https://doi.org/10.1177/1758835920937612
[4]
Notes to Editors
About
Its flagship products are the EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE (EpiSwitch Prostate Screening test) blood tests. CiRT is a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in
In
The Company’s product portfolio is based on a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for the prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer,
The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 15,000 samples in more than 30 human diseases.
OBD is headquartered in
For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow OBD on Twitter (@OxBioDynamics) and LinkedIn.
About EpiSwitch®
The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.
Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 15,000 samples in 30 disease areas, and reduced to practice.
In addition to stratifying patients with respect to anticipated clinical outcomes, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.
About Bupa
Bupa's purpose is helping people live longer, healthier, happier lives and making a better world. Health insurance accounts for a large part of our business with
src="https://cts.businesswire.com/ct/CT?id=bwnewssty=20231018476624r1sid=acqr8distro=nxlang=en" style="width:0;height:0" />
View source version on businesswire.com: https://www.businesswire.com/news/home/20231018476624/en/
+44 (0)1865 518910
Shore Capital
Nominated Adviser and Broker
+44 (0)20 7408 4090
+44 (0)20 7457 2020
[email protected]
Source:
Cyber Supply Chain Risks Highlighted by IUA and CyberCube Report
Travelers: Q3 earnings snapshot
Advisor News
- CFP Board announces CEO leadership transition
- State Street study looks at why AUM in model portfolios is increasing
- Supreme Court to look at ERISA rules in upcoming Cornell case
- FPA announces passing of CEO, succession plan
- Study: Do most affluent investors prefer a single financial services provider?
More Advisor NewsAnnuity News
Health/Employee Benefits News
- Plainfield Mayor Addresses "Misinformation" Regarding Retired Firefighers' Health Benefits
- Senator files bill to "Empower Texans with Health Care Transparency and Shopping Incentives"
- Dozens of people died in Arizona sober living homes as state officials fumbled Medicaid fraud response
- Opinion | The Cost Of Health Insurance In Connecticut Could Skyrocket If Congress Does Not Act
- Health centers brace for possibility of limited funds
More Health/Employee Benefits NewsLife Insurance News
- 10 reasons we must embrace the Northwestern Life Insurance building in Minneapolis
- AM Best Revises Outlooks to Stable for Lincoln National Corporation and Most of Its Subsidiaries
- Aflac Northern Ireland: Helping Children, Caregivers and the Community
- AM Best Affirms Credit Ratings of Well Link Life Insurance Company Limited
- Top 8 trends that will impact insurance in 2025
More Life Insurance News